Viatris Announces Launch Of Bioequivalent Generic For Copaxone In Canada - Quick Facts

(RTTNews) - Viatris Inc. (VTRS) announced the launch in Canada of Glatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, indicated for the treatment of patients with Relapsing-Remitting Multiple Sclerosis. Glatiramer Acetate Injection 20 mg/mL is available by prescription only.

Viatris Canada's Country Manager Jeffrey Long said, "The launch of Glatiramer Acetate Injection 20 mg/mL marks another significant milestone for Viatris Canada, reinforcing our proven capabilities in bringing complex and difficult-to-manufacture products to market, and furthering our commitment to providing access to high quality medicines."

For More Such Health News, visit rttnews.com.